1,029 filings
Page 28 of 52
S-8
cvyq7
18 Aug 17
Registration of securities for employees
12:00am
8-K
eynu v5tcfy7ugsswb4v
18 Aug 17
Departure of Directors or Certain Officers
12:00am
4
35xlu3b9
17 Aug 17
Trovagene / WILLIAM J WELCH ownership change
12:00am
8-K
3670h4
16 Aug 17
Trovagene’s PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy
12:00am
8-K
haos4ru8 91
9 Aug 17
Trovagene Announces Second Quarter 2017 Company Highlights and Financial Results
12:00am
8-K
vg6fj u53
31 Jul 17
Other Events
12:00am
8-K
rvcicxjxwk6ao5 cq
28 Jul 17
Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia
12:00am
8-K
khi8evd
25 Jul 17
Trovagene Announces Peer-Reviewed Publication of First-in-Human Phase 1 Trial Results with PCM-075, its Polo-like Kinase 1 (PLK1) Inhibitor
12:00am
SC 13G
rufdhkdo5f0zgm7if
24 Jul 17
Trovagene, Inc.
12:00am
D
bnsh7th2zm
24 Jul 17
$6.55M in options / securities to be acquired, 4 investors
12:00am
SC 13G
vrifhlp wf0
17 Jul 17
Trovagene, Inc.
12:00am
424B5
ez6p q4cv88hr0s
17 Jul 17
Prospectus supplement for primary offering
12:00am
8-K
m7dk81w0t8qo 75mk
17 Jul 17
Trovagene Announces $7.1 Million Registered Direct Offering
12:00am
8-K
2n5aclog
12 Jul 17
Trovagene Announces Agreement with Novogene for NextCollectâ„¢ in China
12:00am
8-K
nosqi9
10 Jul 17
Other Events
12:00am
SC 13G/A
rexg7f
10 Jul 17
Trovagene, Inc.
12:00am
8-K
ropou6g52543ve
6 Jul 17
Trovagene Engages CRO to Conduct Phase 1b/2 Trial of PCM-075 in AML
12:00am
8-K
5x1wsd0ej9fnnu9
29 Jun 17
Trovagene Announces Manufacturing Agreement with NerPharMa for Supply of PCM-075 for AML Trial
12:00am
8-K
0sn0bu0f24v bp3
27 Jun 17
Trovagene Announces Submission of Investigational New Drug Application to Initiate Phase 1b/2 Clinical Trial of PCM-075 for Acute Myeloid Leukemia
12:00am